No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

HomeACQUISITIONS and MERGERS

Category: ACQUISITIONS and MERGERS

Johnson & Johnson to Acquire...

The acquisition of Shockwave further extends Johnson & Johnson MedTech’s position in cardiovascular intervention and accelerates its shift into higher-growth markets.

Owen Mumford Acquires Empelvic

“The acquisition of Empelvic reinforces our commitment to comprehensive health solutions for intimate conditions,” said Adam Mumford, Director of Medical Devices at Owen Mumford. “By combining Owen Mumford's global expertise with Empelvic's innovative product, we aim to provide enhanced support and choices for individuals seeking pelvic health solutions.”

Johnson & Johnson to Acquire Shockwave Medical

The acquisition of Shockwave further extends Johnson & Johnson MedTech’s position in cardiovascular intervention and accelerates its shift into higher-growth markets.

Allentown LLC Announces the Acquisition of ClorDiSys

ClorDiSys is a family-owned and operated company that began in 2001 as a decontamination equipment provider but quickly added surface-top disinfection products, as well as on-site decontamination services to its portfolio to better address customer challenges

TekniPlex Healthcare Acquires Seisa Medical

Based in El Paso, Texas, Seisa is a medical device manufacturer servicing every stage of the product life cycle including design and development, component manufacturing, and final assembly. It employs more than 2,000 people across four facilities in the U.S., Mexico and Slovakia.

Stryker Announces Intent to Acquire SERF SAS, Enhancing Its Global Joint Replacement Leadership

SERF SAS is recognized by healthcare professionals worldwide for its innovations in hip implants, including the invention of the original Dual Mobility Cup.

Lunit to Acquire Volpara: Scheme Implementation Agreement Signed

Following the decision, Lunit and Volpara have entered into a Scheme Implementation Agreement, under which Lunit will acquire all of Volpara's shares at a price of AUD 1.15 per share through a New Zealand scheme of arrangement (Scheme).

Imbio to be Acquired by 4DMedical Creating Comprehensive Cardiothoracic Image Analysis Portfolio

"Imbio is very excited to join forces with 4DMedical to create the leading lung imaging AI suite in the market, combining 4DMedical's functional analysis with Imbio's anatomical and tissue analysis. Together we can help clinicians around the globe detect disease earlier, make more robust diagnosis, and drive more informed and confident decision-making for better patient care," said Dave Hannes, CEO at Imbio.

Supercell Acquires Exclusive Licensing from Japanese Immunotherapy Leader for Advanced NK Cell Treatment Technology

Supercell, through partnerships in regenerative medicine, has secured an exclusive license for a Japanese-developed natural killer (NK) cell culture technique. The technique, pivotal in cancer cell elimination and immune system enhancement, will be showcased at the expo, highlighting their latest experimental advancement.

Boston Scientific Closes Acquisition of Relievant Medsystems, Inc.

he Intracept system, a basivertebral nerve ablation therapy, will be an addition to the Boston Scientific chronic pain portfolio that includes spinal cord stimulation, radiofrequency ablation and an interspinous spacer procedure.

Probo Medical Completes Acquisition of Davis Medical

"As Probo Medical has grown, we've seen the value of tailoring our commercial offering to the specific needs of specialists that we serve. Davis Medical provides us with exactly that in the cardiology specialty, with decades of experience and a refined approach to support cardiology practices with the equipment, services and supplies they need to run their practice," said Michael Asmer, CEO of Probo. "Additionally, the Davis Medical team adds significant strength to our footprint in the western US."

Shorla Oncology Announces US Acquisition of Jylamvo, an Oncology and Autoimmune Drug from Therakind

“This acquisition will provide a much-needed treatment to patients in need,” said Orlaith Ryan, chief technical officer and co-founder of Shorla Oncology. “It brings a crucial oral treatment to a larger patient population who suffer from cancer and other debilitating illnesses.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy